{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:03:07Z","timestamp":1791068587787,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1136\/ard.2007.077974","type":"journal-article","created":{"date-parts":[[2008,2,13]],"date-time":"2008-02-13T20:59:36Z","timestamp":1202936376000},"page":"1670-1677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":215,"title":["A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies"],"prefix":"10.1016","volume":"67","author":[{"given":"M","family":"Dastmalchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Grundtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Alexanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C P","family":"Mavragani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Einarsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Barbasso","family":"Helmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Elvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M K","family":"Crow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Nennesmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I E","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.077974_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","article-title":"Azathioprine with prednisone for polymyositis. A controlled, clinical trial.","volume":"92","author":"Bunch","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.077974_bib2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1600-0404.1982.tb03087.x","article-title":"Polymyositis \u2013 treatment and prognosis. A study of 107 patients.","volume":"65","author":"Henriksson","year":"1982","journal-title":"Acta Neurol Scand"},{"key":"10.1136\/ard.2007.077974_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0049-0172(92)90006-Y","article-title":"A clinical, serological, and histopathological study of myositis patients with and without anti-RNP antibodies.","volume":"22","author":"Lundberg","year":"1992","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2007.077974_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/art.1780400514","article-title":"Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies.","volume":"40","author":"Lundberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077974_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00005072-199603000-00009","article-title":"Cytokine expression profile in idiopathic inflammatory myopathies.","volume":"55","author":"Tews","year":"1996","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1136\/ard.2007.077974_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0960-8966(98)00126-6","article-title":"Immunolocalization of tumor necrosis factor-\u03b1 and its receptors in inflammatory myopathies.","volume":"9","author":"De Bleecker","year":"1999","journal-title":"Neuromuscul Disord"},{"key":"10.1136\/ard.2007.077974_bib7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/art.20208","article-title":"Association of the proinflammatory haplotype (MICA5.1\/TNF2\/TNFa2\/DRB1*03) with polymyositis and dermatomyositis.","volume":"50","author":"Hassan","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077974_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0165-5728(95)00122-0","article-title":"Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls.","volume":"63","author":"Lundberg","year":"1995","journal-title":"J Neuroimmunol"},{"key":"10.1136\/ard.2007.077974_bib9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s100670070027","article-title":"Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis.","volume":"19","author":"Shimizu","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2007.077974_bib10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/00002281-200311000-00003","article-title":"Cytokines in juvenile dermatomyositis pathophysiology: potential and challenge.","volume":"15","author":"Uzel","year":"2003","journal-title":"Curr Opin Rheumatol"},{"issue":"Suppl 1","key":"10.1136\/ard.2007.077974_bib11","first-page":"S123","article-title":"Pilot trial of etanercept in the treatment of inclusion-body myositis.","volume":"66","author":"Barohn","year":"2006","journal-title":"Neurology"},{"key":"10.1136\/ard.2007.077974_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000070852","article-title":"Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-\u03b1: preliminary observations.","volume":"50","author":"Hengstman","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1136\/ard.2007.077974_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000079547","article-title":"Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-\u03b1: long-term follow-up.","volume":"52","author":"Hengstman","year":"2004","journal-title":"Eur Neurol"},{"key":"10.1136\/ard.2007.077974_bib14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/rheumatology\/keh079","article-title":"Refractory polymyositis responding to infliximab: extended follow-up.","volume":"43","author":"Labioche","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.077974_bib15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/rheumatology\/keh062","article-title":"Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-\u03b1 type II receptor and IgG1.","volume":"43","author":"Sprott","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.077974_bib16","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/rheumatology\/keh268","article-title":"Refractory polymyositis responding to infliximab.","volume":"43","author":"Uthman","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.077974_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2990.1998.00092.x","article-title":"Local expression of cytokines in idiopathic inflammatory myopathies.","volume":"24","author":"Lepidi","year":"1998","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1136\/ard.2007.077974_bib18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts).","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.077974_bib19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts).","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.077974_bib20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies.","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1136\/ard.2007.077974_bib21","first-page":"1380","article-title":"A functional index in myositis.","volume":"23","author":"Josefson","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.077974_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.077974_bib23","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","article-title":"Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.","volume":"40","author":"Miller","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.077974_bib24","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis.","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077974_bib25","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies.","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077974_bib26","first-page":"1591","article-title":"Percutaneous conchotome muscle biopsy. A useful diagnostic and assessment tool.","volume":"28","author":"Dorph","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.077974_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1600-0404.1979.tb02942.x","article-title":"\u201cSemi-open\u201d muscle biopsy technique. A simple outpatient procedure.","volume":"59","author":"Henriksson","year":"1979","journal-title":"Acta Neurol Scand"},{"key":"10.1136\/ard.2007.077974_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0021-9150(99)00011-8","article-title":"Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines.","volume":"145","author":"Frostegard","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1136\/ard.2007.077974_bib29","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/art.22860","article-title":"A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52\/anti-Ro 60 autoantibodies.","volume":"56","author":"Eloranta","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077974_bib30","first-page":"717","article-title":"Subclinical myositis is common in primary Sj\u00f6gren\u2019s syndrome and is not related to muscle pain.","volume":"29","author":"Lindvall","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.077974_bib31","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.20220","article-title":"Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids.","volume":"50","author":"Ulfgren","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077974_bib32","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/art.23062","article-title":"Augmented interferon-\u03b1 pathway activation in patients with Sj\u00f6gren\u2019s syndrome treated with etanercept.","volume":"56","author":"Mavragani","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.077974_bib33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.gene.6364408","article-title":"High serum IFN-\u03b1 activity is a heritable risk factor for systemic lupus erythematosus.","volume":"8","author":"Niewold","year":"2007","journal-title":"Genes Immun"},{"key":"10.1136\/ard.2007.077974_bib34","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0889-857X(02)00027-3","article-title":"Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies.","volume":"28","author":"Rider","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard.2007.077974_bib35","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2005.048744","article-title":"Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.","volume":"65","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.077974_bib36","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/keg388","article-title":"Polymyositis associated with infliximab treatment for rheumatoid arthritis.","volume":"42","author":"Musial","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.077974_bib37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/ard.60.2.133","article-title":"Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNF\u03b1 receptors.","volume":"60","author":"Berg","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.077974_bib38","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-\u03b1\/\u03b2-mediated innate immune mechanisms in dermatomyositis.","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1136\/ard.2007.077974_bib39","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672442685X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672442685X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.077974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:52:57Z","timestamp":1737341577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672442685X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S000349672442685X"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.077974","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1146978.604085","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.077974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 2008 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}